

Jacopo Giuliani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9142329/publications.pdf>

Version: 2024-02-01

104
papers

502
citations

758635

12
h-index

887659

17
g-index

106
all docs

106
docs citations

106
times ranked

575
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-effectiveness of maintenance therapy after first-line treatment in metastatic colorectal cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 194-198.	0.5	1
2	Cost-effectiveness of encorafenib plus cetuximab in BRAF V600E-mutated colorectal cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 107815522110450.	0.5	1
3	Brigatinib is a cost-effective treatment in first-line anaplastic lymphoma kinase mutation-positive (ALK+) advanced non-small cell lung cancer (NSCLC) with brain metastases. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 691-694.	0.5	2
4	Cancer prevales on COVID-19: To maintain high quality standard concerning diagnosis and oncological care even during a pandemic. <i>Journal of Medical Virology</i> , 2021, 93, 118-119.	2.5	6
5	The cost-effectiveness of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer is supported by clinical evidence. <i>Breast Journal</i> , 2021, 27, 75-76.	0.4	3
6	Financial toxicity and cancer treatments: Help from biosimilars – The explanatory case of bevacizumab. <i>European Journal of Cancer</i> , 2021, 143, 40-42.	1.3	19
7	COVID-19 and cancer: A clear change not only in daily clinical practice but also in clinical research management. <i>Journal of Medical Virology</i> , 2021, 93, 2564-2565.	2.5	1
8	To perform genotyping of dihydropyrimidine dehydrogenase (DPD) before starting treatment with 5-fluorouracil or related medicines: really feasible?. <i>International Journal of Colorectal Disease</i> , 2021, 36, 197-198.	1.0	0
9	Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer. , 2021, 4, 740-744.		1
10	Dose-escalation strategy in refractory metastatic colorectal cancer: A change in terms of cost-effectiveness. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 974-977.	0.5	1
11	Psychological impact of Covid-19 pandemic on oncological patients: A survey in Northern Italy. <i>PLoS ONE</i> , 2021, 16, e0248714.	1.1	17
12	Implications of drugs with rebate in Europe. <i>Lancet Regional Health - Europe</i> , The, 2021, 3, 100060.	3.0	19
13	The cost-effectiveness of atezolizumab in first-line for metastatic triple negative breast cancer is heavily linked to PD-L1 level. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 107815522110194.	0.5	2
14	Beyond Abscopal Effect: A Meta-Analysis of Immune Checkpoint Inhibitors and Radiotherapy in Advanced Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 2352.	1.7	15
15	What to Do and What Not to Do in the Management of Cancer Pain: A Physician Survey and Expert Recommendations. <i>Cancer Management and Research</i> , 2021, Volume 13, 5203-5210.	0.9	2
16	Cost-effectiveness of SpaceOAR system during prostate cancer radiation therapy: Really helpful or excess of expectations?. <i>Brachytherapy</i> , 2021, 20, 1341-1342.	0.2	2
17	The cost-effectiveness of new first-line therapies approved in advanced hepatocellular carcinoma. <i>Journal of Oncology Pharmacy Practice</i> , 2021, , 107815522110450.	0.5	3
18	Cost-effectiveness of denosumab in preventing skeletal-related events in bone metastases. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 2000-2003.	0.5	0

#	ARTICLE	IF	CITATIONS
19	Cost-effectiveness of immune checkpoint inhibitors and radiotherapy in advanced non-small cell lung cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2021, , 107815522110389.	0.5	3
20	Cost-effectiveness of consolidation durvalumab after chemo-radiotherapy in stage III non-small-cell lung cancer: A cost-effective change. <i>Journal of Oncology Pharmacy Practice</i> , 2021, , 107815522110453.	0.5	1
21	The role of fentanyl in the treatment of breakthrough cancer pain: Different biotechnologies, different results and different drug costs. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 445-447.	0.5	3
22	Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness. <i>Clinical Colorectal Cancer</i> , 2021, , .	1.0	0
23	Radiotherapy in cancer and rheumatoid arthritis patients: cancer treatment or control of articular flares? We can achieve both. <i>European Review for Medical and Pharmacological Sciences</i> , 2021, 25, 1548-1556.	0.5	1
24	Trifluridine/Tipiracil in heavily pretreated metastatic gastric cancer. A perspective based on pharmacological costs. <i>European Journal of Cancer</i> , 2020, 138, 77-79.	1.3	2
25	Cost-effectiveness of newer regimens for the prophylaxis of chemotherapy-induced nausea and vomiting: review of the literature and real-world data. <i>Current Opinion in Oncology</i> , 2020, 32, 269-273.	1.1	6
26	The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1486-1491.	0.5	12
27	Economic Sustainability of Trifluridine/Tipiracil for the Treatment of Refractory Metastatic Colorectal Cancer in Real Life. <i>Clinical Colorectal Cancer</i> , 2020, 19, e181-e182.	1.0	1
28	Glioblastoma: Prognostic Factors and Predictive Response to Radio and Chemotherapy. <i>Current Medicinal Chemistry</i> , 2020, 27, 2814-2825.	1.2	1
29	Trifluridine/tipiracil or regorafenib in refractory metastatic colorectal cancer: from clinical trials to daily clinical practice. <i>Recenti Progressi in Medicina</i> , 2020, 111, 785-787.	0.8	0
30	Netupitant plus palonosetron is a cost-effective treatment for the prophylaxis of chemotherapy-induced nausea and vomiting in highly and moderately emetogenic cancer treatment. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 505-508.	0.7	6
31	Immune-checkpoint inhibitors in head and neck squamous cell carcinoma: cost-efficacy in second-line treatment based on programmed death-ligand 1 (PD-L1) level. <i>Oral Oncology</i> , 2019, 97, 143-145.	0.8	12
32	The Economic Impact of Biosimilars in Oncology and Hematology: The Case of Trastuzumab and Rituximab. <i>Anticancer Research</i> , 2019, 39, 3971-3973.	0.5	37
33	Financial Toxicity and Non-small Cell Lung Cancer Treatment: The Optimization in the Choice of Immune Check Point Inhibitors. <i>Anticancer Research</i> , 2019, 39, 3961-3965.	0.5	27
34	The Onset of Grade ≥ 3 Neutropenia Is Associated With Longer Overall Survival in Metastatic Colorectal Cancer Patients Treated With Trifluridine/Tipiracil. <i>Anticancer Research</i> , 2019, 39, 3967-3969.	0.5	7
35	Light and shadow on innovative clinical trial designs: reflections from the EORTC-PAMM course on $\hat{\epsilon}$ preclinical and early-phase clinical pharmacology $\hat{\epsilon}$ ™. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 1033-1036.	1.3	4
36	FOLFIRINOX is a cost-effective combination chemotherapy in first-line for advanced pancreatic Cancer. <i>Pancreatology</i> , 2019, 19, 325-330.	0.5	3

#	ARTICLE	IF	CITATIONS
37	Economic sustainability of nivolumab at flat dose for second-line treatment of metastatic non-small cell lung cancer in real life. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 2059-2060.	0.5	4
38	Palbociclib or Ribociclib in First-Line Treatment in Patients With Hormone Receptor-Positive/Human Epidermal Receptor 2-Negative Advanced or Metastatic Breast Cancer? A Perspective Based on Pharmacologic Costs. <i>Clinical Breast Cancer</i> , 2019, 19, e519-e521.	1.1	5
39	Cost-Effectiveness of Second-Line Treatments for Metastatic Renal-Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e258-e262.	0.9	3
40	Colonic Ewing Sarcoma/PNET associated with liver metastases: A systematic review and case report. <i>Pathology Research and Practice</i> , 2019, 215, 387-391.	1.0	10
41	Immunotherapy in first-line for advanced non-small cell lung cancer: a cost-effective choice?. <i>Recenti Progressi in Medicina</i> , 2019, 110, 138-143.	0.8	7
42	Nivolumab Is a Cost-Effective Second-Line Treatment for Metastatic Renal-Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e557-e562.	0.9	15
43	Regorafenib or Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer? A Perspective on the Basis of Pharmacological Costs. <i>Clinical Colorectal Cancer</i> , 2018, 17, e381-e383.	1.0	3
44	Re: Michal Sarfaty, Moshe Leshno, Noa Gordon, et al. Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. <i>Eur Urol</i> . In press. http://dx.doi.org/10.1016/j.eururo.2017.07.041 . <i>European Urology</i> , 2018, 73, e74.	0.9	0
45	Which grade is of clinical benefit in the randomised controlled trials? The example of 54th American Society of Clinical Oncology annual meeting, 2018. <i>European Journal of Cancer</i> , 2018, 104, 233-235.	1.3	15
46	First-line therapies in metastatic colorectal cancer: integrating clinical benefit with the costs of drugs. <i>International Journal of Colorectal Disease</i> , 2018, 33, 1505-1516.	1.0	7
47	Anti-angiogenic agents in second-line treatment for metastatic colorectal cancer: the optimization of pharmacological costs. <i>International Journal of Colorectal Disease</i> , 2018, 33, 1487-1491.	1.0	3
48	Centrosome Linker-induced Tetraploid Segregation Errors Link Rhabdoid Phenotypes and Lethal Colorectal Cancers. <i>Molecular Cancer Research</i> , 2018, 16, 1385-1395.	1.5	13
49	Long-term survival in advanced pancreatic cancer. <i>Recenti Progressi in Medicina</i> , 2018, 109, 352-358.	0.8	0
50	Nivolumab in Second-Line Treatment for Advanced Non-Small-Cell Lung Cancer With Squamous-Cell Histology: A Perspective Based on Pharmacologic Costs. <i>Clinical Lung Cancer</i> , 2017, 18, e363-e365.	1.1	14
51	The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1872-1876.	1.2	4
52	Epidermal growth factor inhibitors in first-line for metastatic colorectal cancer with ras wild-type: a perspective based on pharmacological costs. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 243-248.	0.7	1
53	The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized-controlled trials of tyrosine kinase inhibitors in first-line for advanced non-small cell lung cancer with activating epidermal growth factor receptor mutations. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> . 2017, 17, 5-8.	0.7	5
54	Elderly patients with advanced pancreatic cancer: the generalizability of the results of clinical trials to daily clinical practice. <i>Recenti Progressi in Medicina</i> , 2017, 108, 152-154.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Second-Line Treatment in Elderly Patients With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, e25-e27.	1.1	0
56	The Pharmacological Costs of Complete Liver Resections in Unselected Advanced Colorectal Cancer Patients: Focus on Targeted Agents. A Review of Randomized Clinical Trials. <i>Journal of Gastrointestinal Cancer</i> , 2016, 47, 341-350.	0.6	2
57	The Pharmacological Costs of First-Line Therapies in Unselected Patients With Advanced Colorectal Cancer: A Review of Published Phase III Trials. <i>Clinical Colorectal Cancer</i> , 2016, 15, 277-284.	1.0	16
58	Management of Advanced Pancreatic Cancer in Daily Clinical Practice. <i>Tumori</i> , 2016, 102, 51-58.	0.6	0
59	The Pharmacological Costs for the Management of Skin Toxicity in Patients With Cancer Treated With Epidermal Growth Factor Receptor-Inhibitors. <i>Clinical Lung Cancer</i> , 2016, 17, 471-473.	1.1	2
60	Pharmacologic Costs of Tyrosine Kinase Inhibitors in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations: A Review of Pivotal Phase III Randomized Controlled Trials. <i>Clinical Lung Cancer</i> , 2016, 17, 91-94.	1.1	6
61	Late recurrence (more than 10 years) in early (tumors equal to or smaller than 2 cm) breast cancer patients. <i>Clinical and Translational Oncology</i> , 2016, 18, 859-862.	1.2	0
62	Case Report of a Well-Differentiated Papillary Mesothelioma of the Tunica Vaginalis in an Undescended Testis With Review of Literature. <i>International Journal of Surgical Pathology</i> , 2016, 24, 443-447.	0.4	6
63	The Multidisciplinary Management of Cancer in Daily Clinical Practice: Towards a Community Hospital Comprehensive Cancer Center. <i>Journal of Gastrointestinal Cancer</i> , 2016, 47, 123-124.	0.6	0
64	The role of palliative surgery in the management of advanced pancreatic cancer in patients with biliary and duodenal obstruction. <i>European Journal of Surgical Oncology</i> , 2016, 42, 581-583.	0.5	2
65	Cisplatin versus cetuximab given concomitantly with radiotherapy in non-resectable head and neck squamous cell carcinoma: an open question. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 263-265.	0.8	1
66	The pharmacological costs of complete liver resections in unselected advanced colorectal cancer patients treated with targeted agents. <i>Recenti Progressi in Medicina</i> , 2016, 107, 434-9.	0.8	0
67	Trends in Survival for Patients with Metastatic Breast Cancer: Is Survival Improving?. <i>Tumori</i> , 2015, 101, 347-352.	0.6	13
68	Primary TKI Resistance in Advanced Non-small Cell Lung Cancer with EGFR Mutation: An Open Question. <i>Tumori</i> , 2015, 101, e115-e117.	0.6	5
69	Ampulla of Vater Carcinoma in Real-World Clinical Practice: A Case Series. <i>Tumori</i> , 2015, 101, e75-e78.	0.6	1
70	Thromboembolic Disease in Advanced Colorectal Cancer Treated with Chemotherapy and Bevacizumab: A Case of Real-World Pan-Thrombosis. <i>Tumori</i> , 2015, 101, e32-e33.	0.6	1
71	The Occurrence of Gastrointestinal Stromal Tumors and Second Malignancies. <i>Journal of Gastrointestinal Cancer</i> , 2015, 46, 408-412.	0.6	11
72	Acute Liver Failure Caused by Metastatic Breast Cancer: Can We Expect Some Results from Chemotherapy?. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2541-2543.	1.1	6

#	ARTICLE	IF	CITATIONS
73	The pharmacological costs of complete liver resections in unselected advanced colorectal cancer patients: a review of published Phase II and III trials. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 101-110.	0.7	0
74	Palliative Surgery in the Multidisciplinary Management of Advanced Ovarian Cancer. <i>Journal of Palliative Medicine</i> , 2014, 17, 6-7.	0.6	0
75	The Outcome of Targeted Therapies in Patients with Poor Prognosis Metastatic Renal Cell Carcinoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2014, 29, 298-300.	0.7	0
76	Carboplatin-containing regimens as front-line treatment for advanced non-small-cell lung cancer in two groups of elderly. <i>Journal of Chemotherapy</i> , 2014, 26, 111-116.	0.7	0
77	Spinal tuberculosis simulating metastatic malignancy: An unusual condition. <i>Asian Pacific Journal of Tropical Medicine</i> , 2014, 7, 83-84.	0.4	1
78	Intraperitoneal Hyperthermic Chemotherapy: Which Drugs?. <i>Journal of Gastrointestinal Cancer</i> , 2014, 45, 113-115.	0.6	0
79	Cetuximab/cisplatin and radiotherapy in HNSCC: is there a favorite choice?. <i>Open Medicine (Poland)</i> , 2014, 9, 279-284.	0.6	0
80	Is There a Real Need of Adjuvant Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma?. <i>Journal of Gastrointestinal Cancer</i> , 2014, 45, 396-397.	0.6	0
81	The Coexistence of Second and Third Malignancies in Adult-Onset Cancer Patients. <i>Journal of Gastrointestinal Cancer</i> , 2014, 45, 395-395.	0.6	0
82	A path for diagnosis and therapy of colon cancer: a continuous quality improvement. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2014, 26, 717-23.	0.7	0
83	Targeted agents and oxaliplatin-containing regimens for the treatment of colon cancer. <i>Anticancer Research</i> , 2014, 34, 423-34.	0.5	20
84	The management of skin toxicity during erlotinib in advanced non-small cell lung cancer: how much does it cost?. <i>Cutaneous and Ocular Toxicology</i> , 2013, 32, 248-251.	0.5	5
85	Skin rash during erlotinib for advanced non-small cell lung cancer: is age a clinical predictor?. <i>Archives of Dermatological Research</i> , 2013, 305, 653-658.	1.1	3
86	Liver Metastases from Primary Rectal Cancer: A Multidisciplinary Reverse Approach. <i>Journal of Gastrointestinal Cancer</i> , 2013, 44, 368-369.	0.6	3
87	Primary Malignant Fibrous Histiocytoma of Vater's Papilla: First Reported Case. <i>Journal of Gastrointestinal Cancer</i> , 2013, 44, 366-367.	0.6	4
88	Skin Rash During Cetuximab Treatment in Advanced Colorectal Cancer: is Age a Clinical Predictor?. <i>Journal of Gastrointestinal Cancer</i> , 2013, 44, 241-245.	0.6	7
89	Cancer relating symptoms in homecare cancer patients: which impact in daily clinical practice?. <i>Medical Oncology</i> , 2013, 30, 635.	1.2	0
90	Single-agent bevacizumab as maintenance therapy in metastatic colorectal cancer: how long do we have to continue?. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 147-148.	0.3	0

#	ARTICLE	IF	CITATIONS
91	Multidisciplinary Approach as the Key Factor in the Management of Liver Metastases from Colorectal Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2013, 44, 486-488.	0.6	3
92	Intravenous Midline Catheter Usage: Which Clinical Impact in Homecare Patients?. <i>Journal of Palliative Medicine</i> , 2013, 16, 598-598.	0.6	5
93	The Effect of Palliative Care on the Assistance of Terminally Ill Cancer Patients. <i>Journal of Palliative Medicine</i> , 2013, 16, 826-827.	0.6	1
94	Platinum doublets as first-line treatment for elderly patients with advanced non-small cell lung cancer. <i>Tumori</i> , 2013, 99, 650-5.	0.6	3
95	Gastrointestinal stromal tumors and second primary malignancies before and after the introduction of imatinib mesylate. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2013, 25, 486-7.	0.7	5
96	Off-label prescription of anti-cancer drugs in Italy: what responsibilities?. <i>Tumori</i> , 2013, 99, e190-2.	0.6	0
97	Ovarian Endometrioid Adenocarcinoma With a Yolk Sac Tumor Component in a Postmenopausal Woman: Case Report and Review of the Literature. <i>Clinical Ovarian and Other Gynecologic Cancer</i> , 2012, 5, 31-32.	0.1	4
98	Immunotherapy and Targeted Therapies in Metastatic Renal Cell Carcinoma: Is There a Preferred Sequence?. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012, 27, 513-518.	0.7	3
99	Gastrointestinal Stromal Tumors and Other Malignancies: a Case Series. <i>Journal of Gastrointestinal Cancer</i> , 2012, 43, 634-637.	0.6	13
100	Ovarian cancer in elderly patients: a difference in treatment based on age?. <i>Archives of Gynecology and Obstetrics</i> , 2012, 286, 1545-1548.	0.8	5
101	A severe delayed infusion reaction induced by trastuzumab: a life-threatening condition. <i>Medical Oncology</i> , 2012, 29, 3597-3598.	1.2	5
102	The Management of Skin Toxicity during Cetuximab Treatment in Advanced Colorectal Cancer: How much does it Cost? A Retrospective Economic Assessment from a Single-Center Experience. <i>Tumori</i> , 2012, 98, 408-412.	0.6	8
103	The management of skin toxicity during cetuximab treatment in advanced colorectal cancer: how much does it cost? A retrospective economic assessment from a single-center experience. <i>Tumori</i> , 2012, 98, 408-12.	0.6	2
104	Cost-effectiveness of biweekly cetuximab plus chemotherapy in first-line treatment for RAS wild-type metastatic colorectal cancer. <i>Journal of Oncology Pharmacy Practice</i> , 0, , 107815522211143.	0.5	0